Next Article in Journal
Influence of Melatonin on the Immune System of Fish: A Review
Next Article in Special Issue
Cholesterol Dependent Uptake and Interaction of Doxorubicin in MCF-7 Breast Cancer Cells
Previous Article in Journal
Effects of Antimicrobial Peptide Revealed by Simulations: Translocation, Pore Formation, Membrane Corrugation and Euler Buckling
Previous Article in Special Issue
Epigenetic Silencing of DKK3 in Medulloblastoma
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(4), 7959-7978; doi:10.3390/ijms14047959

Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines

Cell Transplantation and Gene Therapy Institute, Department of Radiology, the Third Xiang Ya Hospital of Central South University, Changsha 410013, China
Center of Molecular Medicine, the First Xiang Ya Hospital of Central South University, Changsha 410078, China
Author to whom correspondence should be addressed.
Received: 28 February 2013 / Revised: 21 March 2013 / Accepted: 1 April 2013 / Published: 11 April 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [1061 KB, uploaded 19 June 2014]   |  


Receptor for Advanced Glycation End Products (RAGE) is an oncogenic trans-membranous receptor overexpressed in various human cancers. However, the role of RAGE in breast cancer development and proliferation is still unclear. In this study, we demonstrated that RAGE expression levels are correlated to the degree of severity of breast cancer. Furthermore, there is a decrease in the proliferation of all sub-types of breast cancer, MCF-7, SK-Br-3 and MDA-MB-231, as a result of the effect of RAGE siRNA. RAGE siRNA arrested cells in the G1 phase and inhibited DNA synthesis (p < 0.05). Moreover, qRT-PCR and Western Blot results demonstrated that RAGE siRNA decreases the expression of transcriptional factor NF-κB p65 as well as the expression of cell proliferation markers PCNA and cyclinD1. RAGE and RAGE ligands can thus be considered as possible targets for breast cancer management and therapy. View Full-Text
Keywords: siRNA; proliferation; breast cancer siRNA; proliferation; breast cancer

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Radia, A.-M.; Yaser, A.-M.; Ma, X.; Zhang, J.; Yang, C.; Dong, Q.; Rong, P.; Ye, B.; Liu, S.; Wang, W. Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines. Int. J. Mol. Sci. 2013, 14, 7959-7978.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top